Original Article Endocrinol Metab 201631284291 httpdxdoiorg103803EnM2016312284 pISSN 2093596X eISSN 20935978 15AnhydroDGlucitol Could Reflect Hypoglycemia Risk Patients Type 2 Diabetes Receiving Insulin Therapy Min Kyeong Kim Hye Seung Jung Soo Heon Kwak Young Min Cho Kyong Soo Park Seong Yeon Kim Department Internal Medicine Seoul National University College Medicine Seoul Korea Background The identification marker hypoglycemia help patients achieve strict glucose control lower risk hypoglycemia 15AnhydroDglucitol 15AG reflects postprandial hyperglycemia patients wellcontrolled diabe tes contributes glycemic variability Because glycemic variability related hypoglycemia aimed evaluate value 15AG marker hypoglycemia Methods We enrolled 18 adults type 2 diabetes mellitus T2DM receiving insulin therapy assessed occurrence hypoglycemia 3month period We measured 15AG level performed survey score severity hypoglycemia applied continuous glucose monitoring CGMS Results 15AG significantly lower high hypoglycemiascore group compared lowscore group Additionally duration insulin treatment significantly longer highscore group Subsequent analyses adjusted dura tion insulin treatment mean blood glucose closely associated 15AG level hypoglycemia risk In adjusted correlation analyses 15AG negatively correlated hypoglycemia score area curve 80 mgdL low blood glucose index CGMS P0068 P0033 P0060 respectively Conclusion 15AG level negatively associated hypoglycemia score determined recall documented hypo glycemia adjusting mean glucose duration insulin treatment As result level marker risk hypoglycemia patients wellcontrolled T2DM receiving insulin therapy Keywords Hypoglycemia 15Anhydroglucitol Diabetes mellitus Type 2 Glycemic variability Continuous glucose monitor ing INTRODUCTION Strict glycemic control important prevent microvascu lar complications diabetes 12 However risk hypo glycemia precludes intensive management Hypoglycemia increase mortality patients type 2 diabetes mellitus T2DM 34 likely impact diabetesre lated cognitive decline related brain deficits 5 Even non severe hypoglycemic episodes decrease patients quality life increase anxiety fear hypoglycemia It reported prevalence hypoglycemia approxi mately 12 30 depending treatment strategy pa tients T2DM patients United States 6 In Korea number patients severe hypoglycemia creasing 7 center reported incidence pa tients severe hypoglycemia requiring intervention Received 19 January 2016 Revised 17 March 2016 Accepted 22 March 2016 Corresponding author Hye Seung Jung Department Internal Medicine Seoul National University College Medicine 101 Daehakro Jongnogu Seoul 03080 Korea Tel 82220722040 Fax 8227629662 Email junghssnuackr Copyright 2016 Korean Endocrine Society This Open Access article distributed terms Creative Com mons Attribution NonCommercial License httpcreativecommonsorg licensesbync40 permits unrestricted noncommercial use distribu tion reproduction medium provided original work properly cited 284 wwweenmorg Endocrinol Metab 201631284291 httpdxdoiorg103803EnM2016312284 pISSN 2093596X eISSN 20935978 126 median 104 years followup 8 Identifying marker hypoglycemia risk help pa tients achieve strict glucose control lower risk hypo glycemia Although clinical characteristics sociated severe hypoglycemia simple mark er mild hypoglycemia Because repetitive episodes hypo glycemia cause severe hypoglycemia 910 prevention mild hypoglycemia important 15AnhydroDglucitol 15AG 1deoxy form glucose circulating polyol body fluid 15AG mainly supplied oral ingestion natural foods evenly distributed tissues organs 15AG level kept constant level healthy people balance intake excretion The mean 15AG level Japanese patients normal glu cose tolerance reported 24775 µgmL 11 Because 15AG similar structure glucose reabsorp tion competitively inhibited glucose renal tubule 12 Therefore blood 15AG level decreases hypergly cemia high glucose level exists renal tubule flecting mean glucose level 1 2weekperiod 13 Although 15AG negatively correlated mean blood glucose MBG hemoglobin A1c HbA1c pa tients T2DM 14 range 15AG observed wide patients similar HbA1c values This trend explained finding 15AG flects postprandial hyperglycemia case HbA1c 1415 In T2DM postprandial hyperglycemia contributes glycemic variability risk fac tors hypoglycemia 16 aging renal insufficien cy progressive insulin deficiency treatment modalities insulin longacting sulfonylureas duration diabetes insulin treatment 1718 Therefore marker post prandial hyperglycemia 15AG reflect burden hypoglycemia patients wellcontrolled T2DM In study evaluated usefulness 15AG marker hypoglycemia patients T2DM receiving sulin therapy METHODS Patients The participants enrolled outpatient clinic Seoul National University Hospital September 2013 September 2014 We recruited 19 75yearold patients T2DM receiving insulin treatment experienced symptoms hypoglycemia documented blood glucose level 80 mgdL 3month period Exclusion criteria included serum creatinine higher 15 mgdL ele vated aspartate aminotransferase AST alanine amino transferase ALT levels times upper range normal This study approved Institutional Review Board Seoul National University Hospital IRB No 1308 054512 Informed consent obtained par ticipants All study procedures carried accordance Declaration Helsinki Questionnaire measurements The participants asked complete Clarkes hypoglyce mia questionnaire 19 modified scoring pa tients T2DM Fig 1 originally devel oped patients type 1 diabetes The possible range scores 2 46 points points assigned item based severity The score subjectively indicated severity hypoglycemia depending patient recollection We obtained patients demographic anthropometric data medical history including duration diabetes medica tions diabetic complications obtained trained nurse Fasting serum 15AG glucose Cpeptide total choles terol triglycerides high density lipoprotein cholesterol low density lipoprotein cholesterol total bilirubin AST ALT creat inine random urine microalbumincreatinine ratio measured participants Continuous glucose monitoring participants The participants underwent glucose monitoring Fig 1 Modified scoring Clarkes hypoglycemia question naire wwweenmorg 285 15AG Reflects Hypoglycemia T2DM Patients Insulin TherapyCopyright 2016 Korean Endocrine Society Meditronic MiniMed Meditronic Northridge CA USA tinuous glucose monitoring CGMS System Gold CGMS recorded interstitial glucose level 5 minutes 72 consecutive hours CGMS data analyzed MiniMed Solutions software 14 From CGMS data determined degree hypoglycemia area curve 80 mgdL AUC80 20 Glucose variability indices calculated EasyGV software webbased applica tion wwweasygvcouk 21 included standard devia tion blood glucose value standard deviation SD weight ed average glucose values 100 mgdL M100 percentage coefficient variation CV mean amplitude glycemic excursion MAGE Jindex low blood glucose index LBGI high blood glucose index HBGI glycemic risk assessment diabetes equation GRADE continuous overall net glyce mic action CONGA M100 indicates measure stability glucose level comparison 100 mgdL CV ratio SD average glucose level MAGE calculated based mean differences consecutive peaks nadirs greater SD mean glu cose level Jindex measure quality glycemic trol based mean SD 22 The LBGI HBGI specifically designed sensitive hypoglycemia hyperglycemia respectively 23 GRADE indicates risk attribution hypoglycemia hyperglycemia 24 CONGA SD differences glucose level predeter mined time window intervals 22 Statistical analysis Statistical analysis data management performed IBM SPSS version 210 IBM Co Armonk NY USA GraphPad Prism 5 GraphPad La Jolla CA USA All data Table 1 Clinical Characteristics Study Subjects Characteristic Age yr Body mass index kgm2 Duration diabetes yr Duration insulin treatment yr Dose insulin IUkg Hypoglycemia score 15AnhydroDglucitol µgmL Fasting blood glucose mgdL Hemoglobin A1c Cpeptide ngmL Total cholesterol mgdL Triglycerides mgdL HDLC mgdL LDLC mgdL Total bilirubin mgdL Aspartate aminotransferase IUL Alanine aminotransferase IUL eGFR mLmin173 m2 Urine albumincreatinine ratio mgg Mean glucose mgdLa MAGE mgdLa AUC80 mgdL dayab Total n18 65296 23419 21397 10663 050012 9950 6425 1385559 7609 083062 1483259 962470 528139 772184 0703 219114 213130 817207 340400 1873446 1403596 044086 Male n11 666113 23521 22794 10967 052013 10578 5514 1433695 7909 058039 1423275 906396 524152 755222 0803 226128 234150 775251 226223 1987433 1490601 064100 Female n7 62963 23118 190106 10262 047011 9039 7833 1310264 7207 122072 1579216 1051589 534126 799115 0602 20997 18193 88193 607648 1580354 1267558 014038 Values expressed meanSD P values obtained Student t test There differences according sex HDLC high density lipoprotein cholesterol LDLC low density lipoprotein cholesterol eGFR estimated glomerular filtration rate MAGE mean amplitude glycemic excursion AUC80 area curve glucose level 80 mgdL aVariables continuous glucose monitoring CGMS study bOnly 13 patients demonstrated hypoglycemia CGMS study 286 wwweenmorg Kim MK et alCopyright 2016 Korean Endocrine Society expressed meanSD Clinical characteristics com pared according sex score group Student t test Tables 1 2 The Pearson correlation coefficient partial correlation coefficient correlation analysis Table 3 Fig 2 The hypoglycemia score 15AG level transformed logarithmically analyses Statistical sig nificance determined P005 RESULTS Clinical characteristics participants A total 18 participants enrolled clinical char acteristics shown Table 1 Men 611 participants The mean age 65296 years HbA1c 7609 hypoglycemia score 9950 15AG lev el 6425 μgmL According CGMS data mean glucose level 1873446 mgdL MAGE 1403 596 mgdL AUC80 044086 mgdL day During 72hour CGMS period participants achieve glucose level 80 mgdL participants reached glucose level 80 mgdL average 21 minutes 049 CGMS period Therefore observe significant hypoglycemia 18 participants Comparisons according sex revealed signifi Table 2 Comparisons according Hypoglycemia Score Variable Hypoglycemia score Age yr Male sex Body mass index kgm2 Duration diabetes yr Duration insulin treatment yr No insulin injection day Insulin dose IUkgday Fasting blood glucose mgdL Hemoglobin A1c 15AnhydroDglucitol µgmL Cpeptide ngmL eGFR mLmin173 m2 Mean glucose mgdLa Standard deviation mgdLa M100 CV MAGE mgdLa J indexa LBGIa HBGIa GRADEa CONGA1h mgdLa AUC180 mgdL daya AUC80 mgdL dayab 29 n9 5920 65778 556 23523 222105 6846 1407 049012 1331503 7808 7730 082045 745172 1945600 508178 326269 27568 1610575 623321 202233 12784 9759 1672408 304288 053076 1024 n9 13938 647116 667 23215 20395 14455 2011 051013 1439636 7409 5108 084078 888224 1811217 647230 275123 349126 1707601 577164 236177 11940 8127 1561194 251133 073118 P value 0001 0830 0629 0730 0690 0006 0229 0519 0695 0370 0040 0960 0150 0643 0255 0618 0138 0730 0711 0737 0814 0495 0473 0620 0742 Values expressed meanSD P values obtained Student t test eGFR estimated glomerular filtration rate M100 weighted average glucose values 100 mgdL CV percentage coefficient variation MAGE mean amplitude glycemic excursion LBGI low blood glucose index HBGI high blood glucose index GRADE glycemic risk assess ment diabetes equation CONGA1h continuous overlapping net glycemic action 1hour period AUC180 area curve glucose level higher 180 mgdL AUC80 area curve glucose level 80 mgdL aVariables continuous glucose monitoring CGMS study bOnly 13 patients demonstrated hypoglycemia CGMS study wwweenmorg 287 15AG Reflects Hypoglycemia T2DM Patients Insulin TherapyCopyright 2016 Korean Endocrine Society G A 5 1 0 1 g o L 15 10 05 0 r0510 P0031a r0468 P0068b Male Female L d g μ G A 5 1 15 10 5 0 r0180 P0476a r0533 P0033b 05 10 Log10 hypoglycemia score 15 A 1 2 3 AUC80 mgdL day 4 B Fig 2 Correlations 15anhydroDglucitol 15AG level hypoglycemia indices A Log 15AG level negatively correlated log hypoglycemia score B The 15AG level negatively correlated area curve glucose level 80 mgdL AUC80 r Pearson correlation coefficient aSimple correlation bAdjustment log mean blood glucose log duration insulin treatment Table 3 Correlation Coefficients 15AG Other Indices Determined Continuous Glucose Monitoring System Study All Subjects 15AG MBG mgdL M100 J index GRADE LBGI HBGI CONGA1h mgdL SD mgdL MAGE mgdL AUC180 mgdL day Time 180 mgdL day ra P valuea 0538c 0551c 0545c 0565c 0257 0548c 0562c 0442 0436 0582c 0522c 0021 0018 0019 0015 0303 0019 0015 0066 0071 0011 0026 rb 0345 0299 0629c 0479 0424 0258 0307 0217 0337 0197 P valueb 0196 0261 0009 0060 0101 0334 0247 0419 0202 0464 r Pearson correlation coefficient 15AG 15anhydroDglucitol MBG mean blood glucose M100 weighted average glucose values 100 mgdL GRADE glycemic risk assessment diabetes equa tion LBGI low blood glucose index HBGI high blood glucose dex CONGA1h continuous overlapping net glycemic action 1hour period SD standard deviation MAGE mean amplitude glycemic excursion AUC180 area curve glucose level higher 180 mgdL aSimple correlation analysis bAdjustment log mean blood glu cose log duration insulin treatment cP005 differences variables Table 1 Comparisons according hypoglycemia score We divided 18 participants groups according 288 wwweenmorg hypoglycemia score Table 2 duration insu lin treatment serum 15AG level significantly differ ent groups insulin dose fasting blood glu cose HbA1c level different Hypoglycemia influenced factors age duration diabetes renal impairment treatment modality 1618 comparable groups However glycemic variability AUC80 significantly different groups Significant correlations 15AG level hypoglycemia indices When performed correlation analysis 15AG hypoglycemia score significant negative relation ship r0510 P0031 Fig 2A After adjusting dura tion insulin treatment mean glucose negative corre lation remained r0468 P0068 In cases hypoglycemia determined CGMS data AUC80 associated 15AG level simple corre lation analysis However adjusting duration insulin treat ment mean glucose revealed significant correlation tween 15AG AUC80 r0533 P0033 Fig 2B Time 80 mgdL associated 15AG level adjusting variables r0536 P0032 data shown Correlation analyses 15AG glycemic indices Because glycemic variability regarded contributor hy poglycemia performed correlation analyses 15 Kim MK et alCopyright 2016 Korean Endocrine Society AG calculations CGMS Table 3 In simple correlation analyses 15AG showed negative correlations indices P0011 0071 LBGI However MBG influences 15AG level 1214 dices glycemic variability 22 Therefore adjusting MBG duration insulin treatment revealed association 15AG LBGI P0060 strengthened asso ciation 15AG GRADE P0009 negated significant correlations 15AG vari ables DISCUSSION In study evaluated 15AG level act simple marker hypoglycemia patients wellcon trolled T2DM receiving insulin therapy As showed study Table 3 15AG level known negative cor relation postprandial hyperglycemia patients T2DM HbA1c 8 1415 indicates significantly increased glycemic variability On hand 15AG negatively correlated shortterm MBG Ta ble 3 1214 Both severe glycemic variability post prandial hyperglycemia low MBG affect 15AG level opposing directions enhance hypoglycemia 1625 Therefore unclear 15AG actually reflects hypo glycemia Even 15AG reflect hypoglycemia clini cal utility uncertain One study demonstrated pa tients high 15AG level associated smaller risk hypoglycemia multiple insulin injection ther apy compared patients receiving conventional insulin thera py 26 The study evaluate direct relationship tween risk hypoglycemia 15AG level As result limited study participants patients wellcontrolled T2DM insulin treatment 15AG level negatively associated hypoglycemia risk level adjusted mean glucose duration insulin treatment Fig 2 We enrolled 18 patients experienced recent hypo glycemia CGMS revealed episodes glucose level 80 mgdL 13 participants reasons discrepancy presumed delay forming CGMS time symptoms Because ques tionnaire administered right enrollment patients cautious insulin doses reducing risk hypoglycemia This discrepancy contributed lack difference AUC80 highscore lowscore groups Table 2 Indeed possibility scores inaccurate mainly dependent patient recall In addition participants patients T2DM adherent self measurements blood glucose compared patients type 1 diabetes As result hypoglycemic events underestimated scoring We indirectly examined potential role 15AG index hypoglycemia demonstrating associations tween 15AG indices glycemic variability related hypoglycemia LBGI GRADE Table 3 These indica tors reflect degree hypoglycemia 2324 LBGI reported significant predictor future severe hy poglycemia 27 Therefore negative correlations 15AG indices adjusting mean glucose rein force possibility 15AG reflects risk hypoglyce mia patients T2DM receiving insulin therapy The limitations study include fact hypo glycemia scoring standardized tool study patients T2DM We Clarke hypoglyce mic questionnaire Fig 1 developed assess im paired awareness hypoglycemia patients type 1 dia betes 19 There standardized questionnaires evalu ating severity hypoglycemia patients T2DM modified scoring Clarke hypoglycemic questionnaire In addition detected hypoglycemia fined glucose level 80 mgdL 348 total period CGMS The relative rarity hypoglycemia likely weakened statistical significance analyses As mentioned failure significant difference AUC80 highscore lowscore groups 053 076 vs 073118 P0742 Table 2 low incidence hypoglycemia During study period including 3 months en rollment episodes hypoglycemia quiring hospitalization emergency department admission situations required assistance person How recurrent hypoglycemia mild easily lievable known risk factor hypoglycemia 910 detrimental effects cardiovascular disease mortality 428 Therefore effort avoid episodes hypoglycemia intermittent monitoring 15 AG helpful patients T2DM receiving insulin therapy especially recently experienced symptoms hypoglycemia It difficult cut point 15AG marker hypoglycemia wwweenmorg 289 15AG Reflects Hypoglycemia T2DM Patients Insulin TherapyCopyright 2016 Korean Endocrine Society validation studies larger populations quired apply 15AG clinic prevent hypoglycemia CONFLICTS OF INTEREST No potential conflict relevant article ported ACKNOWLEDGMENTS This study supported grant Innovative Re search Institute Cell Therapy A062260 Ministry Health Welfare Republic Korea research grant Seoul National University Hospital 0420140520 ORCID Hye Seung Jung httporcidorg0000000202217049 REFERENCES 1 UK Prospective Diabetes Study UKPDS Group Intensive bloodglucose control sulphonylureas insulin com pared conventional treatment risk complica tions patients type 2 diabetes UKPDS 33 Lancet 199835283753 2 Holman RR Paul SK Bethel MA Matthews DR Neil HA 10Year followup intensive glucose control type 2 di abetes N Engl J Med 2008359157789 3 Seaquist ER Miller ME Bonds DE Feinglos M Goff DC Jr Peterson K et al The impact frequent unrecog nized hypoglycemia mortality ACCORD study Diabetes Care 20123540914 4 McCoy RG Van Houten HK Ziegenfuss JY Shah ND Wermers RA Smith SA Increased mortality patients diabetes reporting severe hypoglycemia Diabetes Care 2012351897901 5 Lee JH Choi Y Jun C Hong YS Cho HB Kim JE et al Neurocognitive changes neural correlates pa tients type 2 diabetes mellitus Endocrinol Metab Seoul 20142911221 6 Williams SA Shi L Brenneman SK Johnson JC Wegner JC Fonseca V The burden hypoglycemia healthcare utilization costs quality life type 2 diabetes mellitus patients J Diabetes Complications 201226399 406 290 wwweenmorg 7 Kim JT Oh TJ Lee YA Bae JH Kim HJ Jung HS et al Increasing trend number severe hypoglycemia pa tients Korea Diabetes Metab J 20113516672 8 Yun JS Ko SH Ko SH Song KH Ahn YB Yoon KH et al Presence macroalbuminuria predicts severe hypogly cemia patients type 2 diabetes 10year followup study Diabetes Care 20133612839 9 Seaquist ER Anderson J Childs B Cryer P DagogoJack S Fish L et al Hypoglycemia diabetes report workgroup American Diabetes Association Endocrine Society Diabetes Care 201336138495 10 Adler GK Bonyhay I Failing H Waring E Dotson S Freeman R Antecedent hypoglycemia impairs autonomic cardiovascular function implications rigorous glycemic control Diabetes 2009583606 11 Yamanouchi T Akanuma Y Serum 15anhydroglucitol 15 AG new clinical marker glycemic control Diabetes Res Clin Pract 199424 SupplS2618 12 Yamanouchi T Minoda S Yabuuchi M Akanuma Y Akanuma H Miyashita H et al Plasma 15anhydroD glucitol new clinical marker glycemic control NID DM patients Diabetes 1989387239 13 Buse JB Freeman JL Edelman SV Jovanovic L McGill JB Serum 15anhydroglucitol GlycoMark shortterm glycemic marker Diabetes Technol Ther 2003535563 14 Kim MJ Jung HS HwangBo Y Cho SW Jang HC Kim SY et al Evaluation 15anhydroglucitol marker glycemic variability patients type 2 diabetes melli tus Acta Diabetol 20135050510 15 Dungan KM Buse JB Largay J Kelly MM Button EA Kato S et al 15Anhydroglucitol postprandial hyper glycemia measured continuous glucose monitoring moderately controlled patients diabetes Di abetes Care 20062912149 16 Murata GH Hoffman RM Shah JH Wendel CS Duck worth WC A probabilistic model predicting hypoglyce mia type 2 diabetes mellitus The Diabetes Outcomes Veterans Study DOVES Arch Intern Med 2004164 144550 17 Zammitt NN Frier BM Hypoglycemia type 2 diabetes pathophysiology frequency effects different treat ment modalities Diabetes Care 200528294861 18 Yun JS Ko SH Severe hypoglycemia patients dia betes Diabetes Metab J 2012362734 19 Clarke WL Cox DJ GonderFrederick LA Julian D Schlundt D Polonsky W Reduced awareness hypogly Kim MK et alCopyright 2016 Korean Endocrine Society cemia adults IDDM A prospective study hypo glycemic frequency associated symptoms Diabetes Care 19951851722 20 American Diabetes Association 6 Glycemic targets Dia betes Care 201538 SupplS3340 21 Hill NR Oliver NS Choudhary P Levy JC Hindmarsh P Matthews DR Normal reference range mean tissue glu cose glycemic variability derived continuous glu cose monitoring subjects diabetes different ethnic groups Diabetes Technol Ther 2011139218 22 Jung HS Clinical implications glucose variability chron ic complications diabetes Endocrinol Metab Seoul 20153016774 23 Kovatchev BP Otto E Cox D GonderFrederick L Clarke W Evaluation new measure blood glucose variabili ty diabetes Diabetes Care 20062924338 24 Hill NR Hindmarsh PC Stevens RJ Stratton IM Levy JC Matthews DR A method assessing quality control glucose profiles Diabet Med 2007247538 25 Saisho Y Tanaka C Tanaka K Roberts R Abe T Tanaka M et al Relationships different glycemic variability dices obtained continuous glucose monitoring Prim Care Diabetes 201592906 26 Kishimoto M Yamasaki Y Kubota M Arai K Morishima T Kawamori R et al 15AnhydroDglucitol evaluates daily glycemic excursions wellcontrolled NIDDM Diabetes Care 19951811569 27 Kovatchev BP Cox DJ GonderFrederick LA YoungHy man D Schlundt D Clarke W Assessment risk severe hypoglycemia adults IDDM validation low blood glucose index Diabetes Care 19982118705 28 Goto A Arah OA Goto M Terauchi Y Noda M Severe hypoglycaemia cardiovascular disease systematic view metaanalysis bias analysis BMJ 2013347 f4533 wwweenmorg 291 15AG Reflects Hypoglycemia T2DM Patients Insulin TherapyCopyright 2016 Korean Endocrine Society